At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AVTX Avalo Therapeutics Inc
Market Closed 12-05 16:00:00 EST
17.56
-0.39
-2.17%
盘后17.56
+0.000.00%
18:20 EST
High18.03Low17.21Vol134.18K
Open17.82D1 Closing17.95Amplitude4.57%
Mkt Cap318.43MTradable Cap203.73MTotal Shares18.13M
T/O2.35MT/O Rate1.16%Tradable Shares11.60M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Avalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa
Reuters  ·  12-02
Avalo Therapeutics Unveils Pipeline Progress Highlighting Lead IL-1β Antibody for Hidradenitis Suppurativa
Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely?
Simply Wall St.  ·  11-08
Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely?
Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete
Reuters  ·  11-06
Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete
Avalo Therapeutics reports third quarter revenue of zero dollars
Reuters  ·  11-06
Avalo Therapeutics reports third quarter revenue of zero dollars
Avalo Therapeutics: Cash & Short-Term Investments of About $112 Mln as of Sept 30, Expected to Provide Runway Into 2028
THOMSON REUTERS  ·  11-06
Avalo Therapeutics: Cash & Short-Term Investments of About $112 Mln as of Sept 30, Expected to Provide Runway Into 2028
Avalo Therapeutics Q3 Operating Expenses USD 19.198 Million
THOMSON REUTERS  ·  11-06
Avalo Therapeutics Q3 Operating Expenses USD 19.198 Million
Press Release: Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Dow Jones  ·  11-06
Press Release: Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Avalo Therapeutics Inc expected to post a loss of $1.66 a share - Earnings Preview
Reuters  ·  11-03
Avalo Therapeutics Inc expected to post a loss of $1.66 a share - Earnings Preview
Avalo Therapeutics to Participate in Piper Sandler Annual Healthcare Conference
Reuters  ·  11-03
Avalo Therapeutics to Participate in Piper Sandler Annual Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Anavex Life Sciences (AVXL)
TIPRANKS  ·  10-29
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Anavex Life Sciences (AVXL)
BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa
Reuters  ·  10-29
BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa
Avalo Therapeutics - Lotus Trial Enrolls 250 Patients, Topline Data From Trial Is Expected in Mid-2026.
THOMSON REUTERS  ·  10-29
Avalo Therapeutics - Lotus Trial Enrolls 250 Patients, Topline Data From Trial Is Expected in Mid-2026.
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa
THOMSON REUTERS  ·  10-29
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX)
TIPRANKS  ·  10-17
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX)
Avalo Therapeutics Inc publishes presentation on advancing IL1β therapies for hidradenitis suppurativa
Reuters  ·  10-10
Avalo Therapeutics Inc publishes presentation on advancing IL1β therapies for hidradenitis suppurativa
Avalo Therapeutics Inc. Files Initial Beneficial Ownership Statement for Chief Business Officer Boyd Taylor
Reuters  ·  10-07
Avalo Therapeutics Inc. Files Initial Beneficial Ownership Statement for Chief Business Officer Boyd Taylor
Avalo Therapeutics Files Initial Beneficial Ownership Statement for Director Kevin Robert Lind
Reuters  ·  10-03
Avalo Therapeutics Files Initial Beneficial Ownership Statement for Director Kevin Robert Lind
Avalo Therapeutics appoints Boyd as CBO, Ivanowicz as SVP, Human Resources
TIPRANKS  ·  10-01
Avalo Therapeutics appoints Boyd as CBO, Ivanowicz as SVP, Human Resources
Avalo Therapeutics Announces New Inducement Compensation Plan Amid Leadership Expansion
Reuters  ·  10-01
Avalo Therapeutics Announces New Inducement Compensation Plan Amid Leadership Expansion
Press Release: Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
Dow Jones  ·  10-01
Press Release: Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Introduction

Company Name.
Avalo Therapeutics Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Issue price:
--